April 21, 2024
Transthyretin Amyloid Cardiomyopathy Treatment Market

Transthyretin Amyloid Cardiomyopathy Treatment Market Poised to Grow Owing to Increasing Incidence of ATTR-CM

The transthyretin amyloid cardiomyopathy treatment market has been gaining significant traction over the past few years owing to the increase in diagnosis rate of transthyretin amyloid cardiomyopathy (ATTR-CM). ATTR-CM is a rare cause of heart muscle disease where a protein called transthyretin misfolds and deposits in the heart muscle, causing the heart to thicken and stiffen. The disease severely affects the heart muscles and can potentially lead to heart failure. Currently, two drugs namely patisiran (Onpattro) and inotersen (Tegsedi) have received approval for the treatment of ATTR-CM thus propelling the growth of this market.

The Global transthyretin amyloid cardiomyopathy treatment market is estimated to be valued at US$ 1943.69 Bn in 2024 and is expected to exhibit a CAGR of 8.0% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the transthyretin amyloid cardiomyopathy treatment are DermaSweep Inc., Lifetrons Switzerland AG, Trophy Skin,PMD Beauty, Dermaglow, ImageDerm Inc., Clairderm Medical Aesthetics, Sylvan Company, Altair Instruments, Koninklijke Philips, Microderm GLO Skincare USA, Silhouet-Tone, and Edge Systems LLC. (HydraFacial), among others.

The key opportunities in the market include rising R&D activities for developing new drugs and increasing adoption of minimally invasive therapies for ATTR-CM treatment. Several pharmaceutical companies are conducting clinical trials to develop novel therapies for ATTR-CM.

Globally, North America is expected to dominate the Transthyretin Amyloid Cardiomyopathy Treatment Market Size owing to higher diagnosis rate, favorable reimbursement policies, and presence of major players. However, Asia Pacific is anticipated to exhibit fastest growth due to growing ATTR-CM patient pool and rising healthcare spending in the region.

Market Drivers

Increasing incidence of ATTR-CM disease owing to growing geriatric population susceptible to this disease is a major driver for this market. As per epidemiological studies, over 50,000 Americans suffer from ATTR-CM currently. Moreover, growing awareness about early diagnosis and available treatment options is positively impacting the market growth.

PEST Analysis

Political: Changes in healthcare regulations could impact drugs approvals and reimbursement plans for transthyretin amyloid cardiomyopathy (ATTR-CM) treatment. The rise of single payer healthcare systems may alter pricing and accessibility.

Economic: Slowdowns in the global or local economy could affect spending on high-cost ATTR-CM treatment drugs. Economic recessions may limit healthcare budgets and reimbursements.

Social: Increased diagnosis rates and awareness of ATTR-CM indications could drive demand for treatment options. A growing aging population is also more prone to cardiac amyloidosis.

Technological: Advancements in gene therapy and RNA interference approaches may offer new targets and mechanisms for ATTR-CM treatment in the future. Existing drugs are also working on improving dosage schedules and delivery methods.

Geographical Regions Where Market is Concentrated

The United States is currently the largest market for transthyretin amyloid cardiomyopathy treatment in terms of value, given the high prices of patent-protected drugs and prevalence of hereditary ATTR-CM indications. Europe is the second largest region, led by countries with growing elderly populations like Germany, Italy, France and the UK. Japan also represents a significant share due to having the highest rate of ATTR-CM worldwide.

Fastest Growing Region

Asia Pacific excluding Japan is poised to be the fastest growing regional market for transthyretin amyloid cardiomyopathy treatment. This is driven by economic development, increasing accessibility to novel drugs, and a rising incidence of age-related cardiac amyloidosis in developing nations. Greater awareness and diagnostics are additionally fueling new patient identification and treatment uptake across Southeast Asian and Indian subcontinent markets.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it